Related Experiment Video
Updated: May 20, 2026

07:51
A Novel Approach to Monitoring Graft Neovascularization in the Human Gingiva
Published on: January 12, 2019
Drug-induced gingival overgrowth: a case report
Carla Cecilia Alandia-Roman1, Camila Tirapelli, Paulo Ribas
1Department of Dental Materials and Prosthodontics, Ribeirao Preto School of Dentistry, University of Sao Paulo, Brazil.
General Dentistry
|July 12, 2012
Summary
This case study details a severe drug-induced gingival overgrowth (DIGO) caused by nifedipine. The study outlines the step-by-step reversal of DIGO, highlighting management challenges.
Area of Science:
- Oral Medicine
- Pharmacology
- Periodontology
Background:
- Systemic medications can cause adverse oral effects.
- Drug-induced gingival overgrowth (DIGO) presents significant challenges in patient care.
- Nifedipine is a calcium channel blocker known to potentially cause gingival overgrowth.
Related Concept Videos
The Oral Microbiota
The oral microbiome includes a complex ecosystem comprising over 700 microbial species, identified through genomic sequencing and culture-based analyses to date. This community includes a core microbiome, found universally among individuals, and a variable component influenced by environmental factors such as diet, lifestyle, and host genetics. Site-specific conditions, including oxygen gradients, pH levels, and nutrient availability, determine the spatial distribution of these microorganisms...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
